ePrints

Rituximab and abatacept for rheumatoid arthritis

Lookup NU author(s): Professor John IsaacsORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Estimates from the UK indicate that around 0.5-1.0% of the population have rheumatoid arthritis. Here we assess the place of rituximab (MabThera--Roche Products Ltd) and abatacept (Orencia--Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.

Publication metadata

Author(s): Isaacs JD

Publication type: Article

Publication status: Published

Journal: Drug and Therapeutics Bulletin

Year: 2008

Volume: 46

Issue: 8

Pages: 57-61

Print publication date: 01/08/2008

ISSN (print): 0012-6543

ISSN (electronic): 1755-5248

Publisher: BMJ Group

URL: http://dx.doi.org/10.1136/dtb.2008.07.0017

DOI: 10.1136/dtb.2008.07.0017

Notes: BMJ Group Journal Article England

Altmetrics

Share